Use of glucagon-like peptide type 1 receptor agonists in kidney transplant recipients.

Introduction: In kidney transplant (KT) recipients diabetes mellitus (DM) are associated with an increased mortality and a poorer graft survival. Glucagon-like peptide 1 receptor agonists (GLP1-RA) have demonstrated cardiovascular and renal benefits in the general population. However, there is lacking evidence in KT recipients.

Benefits of Routine Screening for Renal Cell Carcinoma of Native Kidney in Renal Transplant Recipients.

Background: Renal-cell carcinoma (RCC) is the most common solid organ cancer in kidney transplantation recipients (KTRs).

Background: Analyze the incidence, prognosis, and evolution of primitive kidney RCC in KTRs at our institution.

Material And Methods: Observational descriptive retrospective study in which all KTRs from January 2000 to December 2022 were included.